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Supplementary Methods 
Cell lines 
The murine gastric carcinoma cell line mGC8  was provided by W. Zimmermann 
(Munich, Germany) [14], the murine breast cancer cell line 4T1 by M. Wartenberg 
(Jena, Germany) and the murine T cell line B3Z, the packaging cell line Plat-E and the 
HEK-derived cell line 293T by W. Uckert (Berlin, Germany). The human melanoma cell 
lines Mel624.38 was provided by M. Panelli (Bethesda, USA) and MelA375 was 
obtained from ATCC (CRL1619). The colon carcinoma cell line LS174T was obtained 
from ATCC (CLL 188). The human T cell line Jurkat was obtained from Life 
Technologies. The tyrosinase specific T cell clone IVSB was obtained from T. Wölfel 
(Mainz, Germany). mGC8, Plat-E and 293T cells were cultured in DMEM with 10 % 
fetal bovine serum (FBS, Life Technologies, USA), 1 % penicillin and streptomycin 
(PS) and 1% L-glutamine (all from PAA, Germany). 10 μg/ml puromycin and 1 μg/ml 
blasticidin (Sigma, Germany) was added to the Plat-E medium. 4T1, Mel624.38, 
MelA375, LS174T, B3Z, Jurkat cell lines and primary murine and human T cells were 
cultured in RPMI 1640 with 10% FBS, 1% PS and 1% L-glutamine. 1% sodium 
pyruvate, 1 mM HEPES and 50 μM β-mercaptoethanol were added to the T cell 
medium. IVSB T cell clone was cultured in AIM V medium (Life technologies, 
Germany) with 10% human AB serum (Bavarian Red Cross, Germany) 1% L-
glutamine, 1% PS, 1% sodium pyruvate and 50 U/ml of interleukin-2 (Novartis, 
Germany). Phenotypic testing was performed for all cell lines to ensure authenticity. 
 
Antibody generation 
The BiAb against human EGFR and murine EpCAM (ER-Ep BiAb) was 
designed in a two-plus-two tetravalent BiAb format as a murine IgG2a construct 
based on the sequences of MAB225 [28] and of the rat anti-murine EpCAM G8.8 
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(obtained from the Developmental Studies Hybridoma Bank). Sequences of the 
variable regions of MAB225 were cloned into two mammalian expression vectors 
including the mouse IgG2a framework and the kappa light chain backbone constant 
regions. Murinized G8.8 and MAB225 were generated in the same backbone. To 
generate the bispecific construct, a disulfide bridge-stabilized single chain Fv G8.8 
VH-(G4S)3-VL was designed via gene synthesis and fused by a (G4S)2 connector to 
the C-terminus of the MAB225 heavy chain. The bispecific antibody against EGFR 
and c-Met (ER-Met BiAb) was generated from cetuximab and the c-Met antibody 
5D5, respectively  [29]. The bispecific antibody specific for EGFR and for digoxigenin 
(ER-Dig BiAb) was generated from cetuximab and the digoxigenin antibody 
(WO2011/003557) [30]. 
 
Image analysis 
Immunofluorescence slides were analyzed using ImageJ software (version 10.2, 
National Institutes of Health, USA). 
 
Surface plasmon resonance analysis of binding to EGFR and EpCAM by BiAb 
All experiments were performed on Biacore B3000, T100 and T200 instruments in 
running buffer PBS containing 0.05 % (v/v) Tween20. Dilution buffer consisted of 
running buffer supplemented with 1 mg/mL BSA. Standard amine coupling to 
ECD/NHS-activated chip surfaces was performed as recommended by the provider 
(GE Healthcare). Signals were double referenced against blank buffer and a flow cell 
containing no ligand. Kinetic constants were calculated from fitting to a 1:1 Langmuir 
binding model (RI = 0). Single antigen binding were assayed at 37°C, simultaneous 
binding at 25°C.  Antigen was amine-coupled on a C1 sensor chip. For simultaneous 
binding, EGFR was coupled to the chip surface, bispecific antibody was injected and 
upon reaching saturation, a second injection with recombinant EpCAM was 
performed. An additional injection of EpCAM did not further raise the response level. 
 
Immunohistochemistry and immunofluorescence 
Immunohistochemistry and immunofluorescence were performed as described 
[14]. In brief, tumors were removed, embedded in tissue tek OCT medium (Leica, 
Germany) and snap frozen. Tumors were cut in 7 μm sections and transferred to 
microscopy slides which were then fixed with acetone and blocked with 10 % donkey 
serum (Miltenyi). Nuclei were stained using hemalaun (Carl Roth, Karlsruhe, 
Germany) or DAPI hydrochloride (Life Technologies, USA). For detection of antigens, 
anti-EpCAM rat antibody (clone G8.8, Santa Cruz Biotechnology, USA), anti-CD3 
Syrian hamster antibody (clone 500A2, BD Pharmingen, USA), anti-MHC class I 
(clone ER-HR52, AbD Sero Tec, Düsseldorf, Germany) and anti-EGFR antibody 
cetuximab (Merck-Serono, Germany) were used. Anti-rat IgG-Cy2, anti-Syrian 
hamster IgG-biotin, streptavidin-AP and anti-human IgG-FITC were from Jackson 
Immunoresearch, USA. 
 
Flow cytometric analysis of T cell distribution 
Non-tumor bearing mice were treated with the combination of ER-Ep BiAb and 
'EGFR-transduced T cells or T cells with murine anti-EpCAM antibody G8.8. One 
week after treatment, animals were euthanized and organs (spleen, liver, lung, liver 
and small bowel) collected to obtain single cell suspensions. Cell suspensions were 
stained with anti-CD3-FITC and anti-CD8-APC antibodies (both ebioscience, clones 
145-2C11 and clone 53.67). Staining was analyzed using BD FACS Canto II (BD, 
Germany).  
Supplementary Tables 
Supplementary Table 1: summary of the p values for Figure 2B 
Condition 
ER-EpBiAb + 
TCR  
+ 4T1 
ER-Ep 
BiAb + 
TCR + 
B16 
ER-Dig 
BiAb + 
TCR + 
mGC8 
ER-Ep 
BiAb + 
OT1 + 
mGC8 
ER-Ep 
BiAb + 
WT + 
mGC8 
TCR + 
mGC8 
ER-Ep 
BiAb + T 
cell + 
mGC8 0.003 0.001 <0.001 0.040 <0.001 <0.001 
ER-Ep BiAb, anti-EGFR x anti-EpCAM bispecific antibody; TCR, T cell receptor; WT, 
wild type 
Supplementary Table 2: summary of the p values for Figure 3A 
  Days                     
Comparison 42 44 48 49 50 53 54 55 56 57 60 
ER-Ep BiAb + 
'EGFR T cells 
vs PBS 0.039 0.016 0.003 <0.001 <0.001 <0.001  <0.001  <0.001  <0.001  <0.001  
<0.001 
until 
day 62 
ER-Ep BiAb + 
'EGFR T cells 
vs anti-EpCAM 
antibody ns ns 0.004 0.002 <0.001 <0.001  <0.001  <0.001  <0.001  <0.001   
ER-Ep BiAb + 
'EGFR T cells 
vs anti-EpCAM 
antibody + 
'EGFR T cells ns ns ns ns ns ns 0.0137 0.010 0.009 <0.001 
<0.001 
until the 
end 
ER-Ep BiAb, anti-EGFR x anti-EpCAM bispecific antibody 
Supplementary Table 3: summary of the p values for Figure 3B 
  Days                 
Comparison 41 43 47 50 54 61 63 65 68 
ER-Ep BiAb + 
'EGFR T cells 
vs PBS 0.026 0.016 <0.001 <0.001  <0.001  <0.001  <0.001  <0.001    
ER-Ep BiAb + 
'EGFR T cells 
vs anti-EpCAM 
antibody  ns  ns 0.020 0.001 <0.001 <0.001  <0.001  <0.001  <0.001  
ER-Ep BiAb + 
'EGFR T cells 
vs ER-Ep BiAb  ns  ns  ns  ns 0.015 0.001 <0.001 <0.001 
<0.001 
until day 
72 
ER-Ep BiAb + 
'EGFR T cells 
vs murinized 
anti-EpCAM 
antibody + 
'EGFR T cells  ns  ns  ns  ns 0.038 0.017 0.002 <0.001  
 <0.001 
until the 
end 
ER-Ep BiAb, anti-EGFR x anti-EpCAM bispecific antibody. 
 
Supplementary Figure 1: EpCAM is a target for antibody-based therapy in a 
subcutaneous tumor model of a murine gastric cancer. (A) Expression analysis 
of EpCAM on the murine gastric cancer cell line mGC8 by flow cytometry. mGC8 
cells were stained with increasing concentrations of anti-EpCAM antibody G8.8 or 
anti-EGFR antibody MAB225. Results shown are the mean of biological triplicates of 
one experiment, which is representative for three independent experiments. Error 
bars represent standard deviation (SD) (B) Expression of EpCAM and distribution of 
rat anti-EpCAM antibody G8.8 injected i.v. in tumor bearing C57BL/6 mice. For 
expression analysis of EpCAM (black bars), sections of embedded frozen organs 
were stained with rat anti-EpCAM antibody G8.8 followed by anti-rat IgG labelled with 
Cy2. For analysis of rat anti-EpCAM antibody distribution, mice were injected i.p. with 
G8.8 antibody (300 μg) and organs were isolated 48 h later. Rat G8.8 distribution 
was detected with an anti-rat IgG labelled with Cy2. Quantification in both settings 
was performed using ImageJ software. For each organ mean values of three mice 
are shown with SD. (C) Representative staining of tissues taken from mice injected 
with rat anti-EpCAM antibody G8.8 or PBS. Tissues were stained with anti-rat IgG 
antibody labelled with Cy2. Data for the mGC8 subcutaneous tumor and for the 
kidney are shown. Scale bars represent 100 μm.  
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Supplementary Figure 2: (A) Simultaneous binding of human EGFR and murine 
EpCAM ectodomains by the BiAb analyzed by surface plasmon resonance. 
Human EGFR ectodomain was amine-coupled to the sensor chip. ER-Ep BiAb was 
injected at time point -450 s. At 0 s, recombinant EpCAM (333 nM) or saline was 
injected.  (B) 'EGFR expression after T cell transduction. Primary murine T cells or 
the T cell line (B3Z) were retrovirally transduced with 'EGFR and stained with 
monoclonal anti-EGFR antibody. Histogram is representative for all cell transductions 
performed in the presented experiments. 
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Supplementary Figure 3: Enhanced T cell infiltration in the tumors of mice treated 
with the combination of anti-EGFR x anti-EpCAM bispecific antibody and adoptive 
transfer of 'EGFR-transduced T cells. (A) T cell infiltration in EpCAM+ murine organs 
(spleen, liver, lung, kidney and small bowel) was analyzed by flow cytometry of tissue-
derived cell suspensions. Mice (n = 3 for each condition) were treated with 10 mg/kg  
anti-EGFR x anti-EpCAM bispecific antibody (ER-Ep BiAb) and 107 'EGFR-transduced 
TCR-I T cells or with 10 mg/kg murinized anti-EpCAM antibody and 107 'EGFR-
transduced TCR-I T cells. One week later, the animals were euthanized and single cell 
suspensions were stained for CD3 and CD8. No difference in the number of infiltrating T 
cells was found. Results are representative of two experiments performed with three 
mice per group. Each dot represents one mouse; bars represent SD. (B) Quantification 
of infiltrating CD3 positive T cells per 30 high power fields (HPF) in mice treated with 
PBS (n=11), anti-EGFR x anti-EpCAM bispecific antibody (n=6), anti-EpCAM antibody 
(n=13), anti-EpCAM antibody plus anti-EGFR antibody plus 'EGFR-transduced T cells 
(n=12) or anti-EGFR x anti-EpCAM bispecific antibody plus 'EGFR-transduced T cells 
(n=17). Tumors were harvested from mice which had to be euthanized due to tumor 
size. Data are pooled from experiments shown in Figure 3. Groups were compared 
using unpaired Student’s t-test. Bars represent SD. (C) Representative 
immunohistochemistry of an untreated tumor in 40x magnification. Hemalaun and anti-
CD3-AP co-staining. (D) Representative immunohistochemistry of a tumor treated with 
the combination of anti-EGFR x anti-EpCAM bispecific antibody and 'EGFR-transduced 
T cells in 40x magnification. Hemalaun and anti-CD3-AP co-staining. Arrows indicate 
positively stained cells. Scale bars in C and D represent 100 ȝm.
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